9 questions answered from cited research · Plain language
Yes, maternal RSV vaccination and the infant monoclonal antibody nirsevimab work together to protect babies, with nirsevimab providing the primary shield for the first RSV season.
Read the full answer →Yes, nirsevimab prevents RSV in infants born in October 2023, reducing hospitalizations by 70–90% during their first RSV season.
Read the full answer →RSV and COVID-19 cause similar severe outcomes in older adults, including ICU admission and death, but RSV may pose higher risk of acute cardiac events.
Read the full answer →Nirsevimab is being rolled out for infants in New York City and is recommended for high-risk groups including those living with HIV or exposed to HIV.
Read the full answer →In low-income countries, severe RSV outcomes like hospitalization and death peak in infants between 2 and 5 months of age.
Read the full answer →Yes, specific assays like whole-genome sequencing developed in Georgia have shown high accuracy for detecting respiratory syncytial virus in clinical specimens.
Read the full answer →RSV and human metapneumovirus co-circulate in the US, especially during winter and spring, with overlapping seasonal patterns and similar disease spectra.
Read the full answer →As of December 2023, RSV vaccination coverage among US nursing home residents was about 9.8%, with limited data for other adults.
Read the full answer →Safety data from a year after the RSV vaccine was recommended for adults 60 and older shows no significant difference in serious adverse events compared to a placebo.
Read the full answer →